surmount-1 tirzepatide weight loss non-diabetic (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT Clinical Trials Orals Session
Description
Your Concierge Support Your care team LunaRx is led by Anamaria Galvan, RN eight years of clinical experience and ten years in pharmacy alongside independent, U.S.-licensed physicians
Incretin receptor agonists, including tirzepatide, may potentially increase the risk of thyroid C-cell tumors based on findings in animal studies
thus, it should be considered in patients with a history of ASCVD
The injections are administered subcutaneously, with Wegovy and Zepbound given weekly and Saxenda administered daily, using pre-filled pens similar to insulin delivery devices
